Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | CCKBR | P32239 | 2/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | PDE5A | O76074 | 3/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1921589 | 0.90 | CCKBR (0.80) | KDM4EALDH1A1CCKBRCYP2D6MAPK1 | |
| SCHEMBL11246437 | 0.89 | CCKBR (0.78) | KDM4EALDH1A1CCKBRCYP2D6MAPK1 | |
| SCHEMBL1921741 | 0.85 | KDM4E (0.65) | KDM4EALDH1A1CCKBRCYP2D6MAPK1 | |
| SCHEMBL1921543 | 0.84 | KDM4E (0.64) | KDM4EALDH1A1CCKBRCYP2D6MAPK1 | |
| SCHEMBL1921371 | 0.83 | KDM4E (0.63) | KDM4EALDH1A1CCKBRCYP2D6MAPK1 | |
| SCHEMBL28127168 | 0.82 | ALDH1A1 (0.77) | KDM4EALDH1A1CCKBRCYP2D6MAPK1 | |
| SCHEMBL1921587 | 0.82 | KDM4E (0.66) | KDM4EALDH1A1CCKBRCYP2D6MAPK1 | |
| SCHEMBL1921530 | 0.81 | KDM4E (0.65) | KDM4EALDH1A1CCKBRCYP2D6MAPK1 | |
| SCHEMBL15384065 | 0.81 | KDM4E (0.74) | KDM4EALDH1A1CCKBRCYP2D6MAPK1 | |
| SCHEMBL16892184 | 0.81 | KDM4E (0.98) | KDM4EALDH1A1CCKBRCYP2D6MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2327408-A1 | Tetracyclic cyclic gmp-specific phosphodiesterase inhibitors for the treatment of benign prostatic hypertrophy | ICOS Corporation (US) | 2011-06-01 | — | — | EP | disclosed |
| EP-2036560-A1 | (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione for the treatment of benign prostatic hypertrophy | ICOS Corporation (US) | 2009-03-18 | — | — | EP | disclosed |
| US-6784179-B2 | treating a vascular disease by administering e.g. tadalafil in combination with an endothelium-derived relaxing factor, an atrial natriuretic factor, a brain natriuretic peptide, a C-type natriuretic peptide, or an endothelium-dependent relaxing agent such as serotonin | ICOS CORPORATION | 2004-08-31 | — | — | US | disclosed |
| US-20020119976-A1 | Tetracyclic derivatives, process of preparation and use | ICOS CORPORATION | 2002-08-29 | — | — | US | disclosed |
| US-6369059-B1 | INHIBITOR OF CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE SPECIFIC PHOSPHODIESTERASE (CGMP SPECIFIC PDE); CARDIOVASCULAR DISORDERS; PYRAZINO(2',1':6,1)PYRIDO(3,4-B)INDOLE-1,4-DIONES | ICOS CORPORATION | 2002-04-09 | — | — | US | disclosed |
| EP-0859778-B1 | TETRAHYDROIMIDAZOPYRIDOINDOLEDIONES AS INHIBITORS OF cGMP SPECIFIC PDE | ICOS CORP (US) | 2001-12-19 | — | — | EP | disclosed |
| US-6218400-B1 | TREATING ANGINA, HYPERTENSION, PULMONARY DISEASE, VASCULAR DISORDERS, STROKE, BRONCHITIS, ASTHMA, RHINITIS, GLAUCOMA, SEXUAL DISORDERS, AND DISORDERS OF GUT MOTILITY | ICOS CORPORATION | 2001-04-17 | — | — | US | disclosed |
| US-6143746-A | Combination of tadalafil and another drug for cGMP-specific PDE inhibition; erectile dysfunction, cardiovascular disorders | ICOS CORPORATION (US) | 2000-11-07 | — | — | US | disclosed |
| US-6143757-A | DRUGS FOR CARDIOVASCULAR OR SEXUAL DISORDERS | ICOS CORPORATION (US) | 2000-11-07 | — | — | US | disclosed |
| US-6127542-A | CHEMICAL INTERMEDIATES TO SPECIFIED PYRAZINO(2',1':6,1)PYRIDO(3,4B)INDOLE-1,4-DIONES WHICH ARE SELECTIVE INHIBITORS OF CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE SPECIFIC PHOSPHODIESTERASE; TO TREAT CARDIOVASCULAR DISORDERS | ICOS CORPORATION (US) | 2000-10-03 | — | — | US | disclosed |
| US-6025494-A | CYCLIZATION OF DICARBONYL-SUBSTITUTED PYRIDOINDOLES YIELDS PHOSPHODIESTERASE INHIBITORS | ICOS CORPORATION (US) | 2000-02-15 | — | — | US | disclosed |
| US-6001847-A | 5,6,11,11A-TETRAHYDRO-1H-IMIDAZO(1'5':1,6)PYRIDO(3,4-B)INDOLE -1,3(2H)-DIONE DERIVATIVES; INHIBITORS OF CGMP SPECIFIC PHOSPHODIESTERASE; CARDIOVASCULAR DISORDERS; ERECTILE DYSFUNCTION | ICOS CORPORATION (US) | 1999-12-14 | — | — | US | disclosed |
| EP-0740668-B1 | TETRACYCLIC DERIVATIVES, PROCESS OF PREPARATION AND USE | ICOS CORP (US) | 1998-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119976-A1 | Tetracyclic derivatives, process of preparation and use | PDE3A, PDE3B, PDE2A | KDM4E 3129/4885ALDH1A1 259/4885CCKBR 1367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.